Search - tctmd.com

Displaying 141 - 160 of 265

Sort: Relevancy | Date

Presentation TCT 2016

When Everything Has Disappeared: Role of Cell-Based Engineered Tissue and Organ Transplantation.

Presenter: Timothy D. Henry, Amit N. Patel, Doris A. Taylor

October 31, 2016

Presentation TCT 2016

When Cells are Not Enough: Role of Cellular and Non-Cellular Injectable Biomaterials

Presenter: Timothy D. Henry, Amit N. Patel

October 31, 2016

Presentation TCT 2016

Site-reported vs Core Lab Syntax Scores: Discordance and Impact on Outcomes After PCI vs CABG in EXCEL

Presenter: A. Pieter Kappetein, Marie-Claude Morice, Philippe Généreux

October 31, 2016

Presentation TCT 2016

Improving Translational Science In Cardiac Regenerative Medicine. Utility of Animal Models

Presenter: Timothy D. Henry, Amit N. Patel, Steven A.J. Chamuleau

October 31, 2016

Presentation TCT 2016

Obstacles for Clinical Research: Perspectives From Industry

Presenter: Emerson C. Perin, Ricardo Sanz-Ruiz, Warren Sherman

October 31, 2016

Presentation TCT 2016

Obstacles for Clinical Research: The BAMI Experience

Presenter: Emerson C. Perin, Ricardo Sanz-Ruiz

October 31, 2016

Presentation TCT 2016

Regenerative Products In Perspective: Do They Really Work? Are They Enough?

Presenter: Emerson C. Perin, Ricardo Sanz-Ruiz, Jens Kastrup

October 31, 2016

News Conference News TCT 2016

EXCEL y NOBLE: Los Resultados Contrarios Plantean un Dilema a la Hora de Elegir entre PCI y CABG en el Manejo de la Enfermedad de Tronco Coronario Izdo.

Michael O'Riordan

October 31, 2016

News Conference News TCT 2016

EXCEL and NOBLE: Opposing Results Pose Quandary for PCI/CABG Choice in Left Main Disease

Michael O'Riordan

October 31, 2016

Presentation TCT 2016

Differences Between US and Japan in OAT Discontinuation and Risk of Major Bleeds, and Who are the Best LAA Closure Device Candidates in Both Countries

Presenter: Mitchell W. Krucoff, Shigeru Saito, Christopher B. Granger

October 30, 2016

Presentation TCT 2016

TCT 513: Discordance In Stenosis Classification by Pressure-Only Indices of Stenosis Severity is Related to Differences in Coronary Flow Reserve the RESOLVING DISCORD Study

Presenter: Michalis Hamilos, Pim A.L. Tonino

October 30, 2016

News Conference News TCT 2016

LEADERS FREE: Polymer-Free DES Maintains Superior Safety, Efficacy Over BMS at 2 Years

Yael L. Maxwell

October 30, 2016

News Conference News TCT 2016

Transcaval TAVR Presents New Option for Patients With Complex Anatomy

Yael L. Maxwell

October 29, 2016

Presentation TCT 2015

First-in-Man Experience With Human Embryonic Stem Cell-Derived Progenitors for Heart Failure

Presenter: Francisco Fdez-Aviles, Timothy D. Henry, Philippe Menasché

October 15, 2015

Presentation TCT 2015

Debate: Are We Really Ready for Phase III Trials? For Limb Ischemia There Are Knowns and Unknowns!

Presenter: Francisco Fdez-Aviles, Timothy D. Henry, Amit Patel

October 15, 2015

$Debate: Are We Really Ready for Phase III Trials? For Refractory Angina There Are Knowns and Unknowns!$

Presentation TCT 2015

Debate: Are We Really Ready for Phase III Trials? For Refractory Angina There Are Knowns and Unknowns!

Presenter: Francisco Fdez-Aviles, Timothy D. Henry

October 15, 2015

Presentation TCT 2015

Debate: Are We Really Ready for Phase III Trials? Yes, Mesenchymal Cells Are Ready to Be Tested for Prevention and Treatment of Chronic Ischemic and Nonischemic Heart Failure!

Presenter: Francisco Fdez-Aviles, Timothy D. Henry, Emerson C. Perin

October 15, 2015

Presentation TCT 2015

Debate: Are We Really Ready for Phase III Trials? Yes, in STEMI Bone Marrow Mononuclear Fraction Is Ready, and Other Options Are Coming!

Presenter: Francisco Fdez-Aviles, Timothy D. Henry, Ricardo Sanz-Ruiz

October 15, 2015

Presentation TCT 2015

Debate: Is It Necessary to Implant 3-D Cardiac Structures? In Which Setting? With Micro and Nanotechnology in Cardiovascular Tissue Engineering!

Presenter: Francisco Fdez-Aviles, Emerson C. Perin, Kevin E Healy

October 15, 2015

Presentation TCT 2015

Debate: Is It Necessary to Implant 3-D Cardiac Structures? In Which Setting? But Power Is Nothing Without Control Electromechanical Engraftment!

Presenter: Francisco Fdez-Aviles, Emerson C. Perin, Andreu M Climent

October 15, 2015

Advertisement

When Everything Has Disappeared: Role of Cell-Based Engineered Tissue and Organ Transplantation.

When Cells are Not Enough: Role of Cellular and Non-Cellular Injectable Biomaterials

Site-reported vs Core Lab Syntax Scores: Discordance and Impact on Outcomes After PCI vs CABG in EXCEL

Improving Translational Science In Cardiac Regenerative Medicine. Utility of Animal Models

Obstacles for Clinical Research: Perspectives From Industry

Obstacles for Clinical Research: The BAMI Experience

Regenerative Products In Perspective: Do They Really Work? Are They Enough?

EXCEL y NOBLE: Los Resultados Contrarios Plantean un Dilema a la Hora de Elegir entre PCI y CABG en el Manejo de la Enfermedad de Tronco Coronario Izdo.

EXCEL and NOBLE: Opposing Results Pose Quandary for PCI/CABG Choice in Left Main Disease

Differences Between US and Japan in OAT Discontinuation and Risk of Major Bleeds, and Who are the Best LAA Closure Device Candidates in Both Countries

TCT 513: Discordance In Stenosis Classification by Pressure-Only Indices of Stenosis Severity is Related to Differences in Coronary Flow Reserve the RESOLVING DISCORD Study

LEADERS FREE: Polymer-Free DES Maintains Superior Safety, Efficacy Over BMS at 2 Years

Transcaval TAVR Presents New Option for Patients With Complex Anatomy

First-in-Man Experience With Human Embryonic Stem Cell-Derived Progenitors for Heart Failure

Debate: Are We Really Ready for Phase III Trials? For Limb Ischemia There Are Knowns and Unknowns!

Debate: Are We Really Ready for Phase III Trials? For Refractory Angina There Are Knowns and Unknowns!

Debate: Are We Really Ready for Phase III Trials? Yes, Mesenchymal Cells Are Ready to Be Tested for Prevention and Treatment of Chronic Ischemic and Nonischemic Heart Failure!

Debate: Are We Really Ready for Phase III Trials? Yes, in STEMI Bone Marrow Mononuclear Fraction Is Ready, and Other Options Are Coming!

Debate: Is It Necessary to Implant 3-D Cardiac Structures? In Which Setting? With Micro and Nanotechnology in Cardiovascular Tissue Engineering!

Debate: Is It Necessary to Implant 3-D Cardiac Structures? In Which Setting? But Power Is Nothing Without Control Electromechanical Engraftment!

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content